Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development.
 
We are looking for extraordinary individuals to join our motivated team in taking on our generation’s biggest healthcare challenges: ALS, Parkinson’s Disease, and Alzheimer's Disease. Our employees are our most important asset; we are a team of founders, excited to learn, roll up our sleeves, and make a real impact.
 
The startup nature of Verge Genomics provides multiple growth opportunities into other areas of the company. As one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, on-site gym access, and free lunch.
 
Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Agent Capital

ALS Investment Fund

Basis Set Ventures

OS Fund

Lifeforce Capital

Threshold

WuXi AppTec

Jonathan Downey

BlackRock

Section 32 Alumni Ventures

Merck Global Health Innovation Fund

Tao Capital Partners

Vulcan Capital

Eli Lilly

Verge Genomics

On Thursday, our Chief Medical Officer, Diego Cadavid, will join other leaders, patients, and regulatory organizations at the TRICALS Masterclass to discuss advances in clinical trial designs. If you're there, don't miss him share his expertise and experience designing innovative #ALS clinical trials. For more information, visit https://bit.ly/49Ei1ev. 

#clinicaltrials #innovation #ALSResearch

Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28th, from 10:45 a.m. - 11:15 a.m. EST. If you are attending, watch Alice's presentation to learn more about Verge's innovative strides in transforming drug discovery and development using #AI and human data. https://bit.ly/42LDaBa 

#Investors #Biotechnology #Innovation #EvercoreISIConference2024

Biotech has long recognized the benefits of using digital endpoints in clinical trials. Putting it into practice has been another matter. Our CMO, Diego Cadavid, spoke to BioCentury Inc. about how Verge is paving the way with a digital-first approach in our proof-of-concept study for #ALS, including incorporating digital endpoints that measure mobility, speech and sleep. Read the article here: https://bit.ly/3I0WjFH

#digitalhealth #biotechnology #clinicaltrials


📢 Reminder: Don't miss CEO & co-founder Alice Zhang’s presentation at the J.P. Morgan Healthcare Conference tomorrow! Alice will share how our AI-powered CONVERGE® platform and patient data are accelerating drug discovery and highlight recent company milestones, including the initiation of our cutting-edge proof-of-concept trial for VRG50635, one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. 

#JPM24 #VergeGenomics #CEOInsights #AI #JPMWeek

We are thrilled to share the continued progress of our lead drug candidate, VRG50635 with the initiation of a cutting-edge proof-of-concept study for the treatment of #ALS. By leveraging our AI-enabled CONVERGE® platform in combination with patient data and our novel study design, we're enabled to more efficiently discover and develop potential drugs for deadly diseases like ALS. Learn more: https://bit.ly/3HbVNEp 

#JPM24 #DrugDevelopment #Innovation #AI

Delta4 is a biotech company focused on AI-powered drug discovery for complex and rare diseases. The company offers a platform called Hyper-C, which uses artificial intelligence to discover new indications for drugs with known safety profiles by analyzing drug models against disease profiles.

Delta4

Atomwise is a competitor of Verge Genomics. It is a company that uses artificial intelligence for drug discovery.

Atomwise

Deep Genomics is another competitor of Verge Genomics. It is a company focused on AI-driven drug discovery and development.

Deep Genomics

Genesis Therapeutics is a competitor of Verge Genomics. It is a company specializing in AI-driven drug discovery and development for various diseases.

Genesis Therapeutics

Verge Genomics has pioneered an advanced all-in-human, artificial intelligence powered drug discovery platform to develop better drugs faster for major medical challenges.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 5, 2024 9:14 AM	6790b536
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 9:14 AM	84fde907
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 5, 2024 9:14 AM	8dcfb345
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 9:14 AM	bd61a189
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:VERGEGENOMICS

Verge Genomics